IP Library Granted Patent US 8,058,273
Granted Patent B2
US 8,058,273 · App. 12/791,465 · Granted Nov 15, 2011

Histone deacetylases inhibitors

Assignee: DAC S.R.L.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,058,273
App. No.
12/791,465
Granted
Nov 15, 2011
Kind
B2
Abstract

New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R 1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R 3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.

Claims (82)

1. A method of treating tumor diseases associated to the deregulation of the activity of histone deacetylases in a subject in need thereof, said tumor diseases selected among colon tumor, breast tumor, prostate tumor, lymphoma and cutaneous tumor, said method comprising administering to said subject, in an amount effective to treat said tumor diseases associated to the deregulation of the activity of histone deacetylases, a compound of formula (I)

wherein:

R 3 is chosen among hydrogen, alkoxyalkyl;

Ar is an optionally substituted aryl or heteroaryl group;

A is chosen among:

wherein R 2 is chosen among hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, halogen, haloalkyl, hydroxy, hydroxyalkyl, alkoxy, haloalkoxy, amino, aminoalkyl, alkylamino, (thio)carbonylamino, (thio)aminocarbonil, sulphonylamino, aminosulphonyl, (thio)acyl, (thio)acyloxy, (thio)alkoxycarbonyl, nitro and nitryl;

R 1 is chosen among:

wherein Y represents O, S, NH, CH 2 , NOH or NOR 5 where R 5 is an alkyl having from 1 to 4 carbon atoms.

2. The method of claim 1 , wherein the compound of formula (I) is chosen from:

3-[3-fluoro-4-(3-oxo-3-phenyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-[3-chloro-4-(3-oxo-3-phenyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-[3-chloro-4-(3-oxo-3-o-tolyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-{3-chloro-4-[3-(2-methoxy-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{3-chloro-4-[3-(2-fluoro-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{3-chloro-4-[3-(2-chloro-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-[3-chloro-4-(3-oxo-3-m-tolyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-{3-chloro-4-[3-(3-methoxy-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{3-chloro-4-[3-(3-fluoro-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{3-chloro-4-[3-(3-chloro-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-[3-chloro-4-(3-oxo-3-p-tolyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-{3-chloro-4-[3-(4-methoxy-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{3-chloro-4-[3-(4-fluoro-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{3-chloro-4-[3-(4-chloro-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-[3-chloro-4-(3-oxo-3-thiophen-2-yl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-[3-fluoro-4-(3-oxo-3-o-tolyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-{3-fluoro-4-[3-(2-methoxy-phenyl)-3-oxo-propenyl]phenyl}-N-hydroxy-acrylamide;

3-{3-fluoro-4-[3-(2-fluoro-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{4-[3-(2-chloro-phenyl)-3-oxo-propenyl]-3-fluoro-phenyl}-N-hydroxy-acrylamide;

3-[3-fluoro-4-(3-oxo-3-m-tolyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-{3-fluoro-4-[3-(3-methoxy-phenyl)-3-oxo-propenyl]phenyl}-N-hydroxy-acrylamide;

3-{3-fluoro-4-[3-(3-fluoro-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{4-[3-(3-chloro-phenyl)-3-oxo-propenyl]-3-fluoro-phenyl}-N-hydroxy-acrylamide;

3-[3-fluoro-4-(3-oxo-3-p-tolyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-{3-fluoro-4-[3-(4-methoxy-phenyl)-3-oxo-propenyl]phenyl}-N-hydroxy-acrylamide;

3-{3-fluoro-4-[3-(4-fluoro-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{4-[3-(4-chloro-phenyl)-3-oxo-propenyl]-3-fluoro-phenyl}-N-hydroxy-acrylamide;

3-[3-fluoro-4-(3-oxo-3-thiophen-2-yl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-{3-fluoro-4-[3-(4-morpholin-4-yl-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

N-hydroxy-3-{4-[3-(2-methoxy-phenyl)-3-oxo-propenyl]-phenyl}-acrylamide;

N-hydroxy-3-{4-[3-oxo-3-(2-trifluoromethyl-phenyl)-propenyl]-phenyl}-acrylamide;

N-hydroxy-3-{4-[3-oxo-3-(2-trifluoromethoxy-phenyl)-propenyl]-phenyl}-acrylamide;

3-{4-[3-(2-bromo-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

N-hydroxy-3-{4-[3-(3-methoxy-phenyl)-3-oxo-propenyl]-phenyl}-acrylamide;

3-{4-[3-(3-bromo-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

N-hydroxy-3-{4-[3-(4-methoxy-phenyl)-3-oxo-propenyl]-phenyl}-acrylamide;

N-hydroxy-3-{4-[3-oxo-3-(4-trifluoromethyl-phenyl)-propenyl]-phenyl}-acrylamide;

N-hydroxy-3-{4-[3-oxo-3-(4-trifluoromethoxy-phenyl)-propenyl]-phenyl}-acrylamide;

3-{4-[3-(4-bromo-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

3-{4-[3-(4-diethylamino-phenyl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

N-hydroxy-3-{4-[3-(4-morpholin-4-yl-phenyl)-3-oxo-propenyl]-phenyl}-acrylamide;

3-[4-(3-furan-2-yl-3-oxo-propenyl)-phenyl]-N-hydroxy-acrylamide;

N-hydroxy-3-[4-(3-oxo-3-thiophen-2-yl-propenyl)-phenyl]-acrylamide;

N-hydroxy-3-{4-[3-oxo-3-(1H-pyrrol-2-yl)-propenyl]-phenyl}-acrylamide;

3-[4-(3-benzofuran-2-yl-3-oxo-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-[4-(3-benzo[b]thiophen-2-yl-3-oxo-propenyl)-phenyl]-N-hydroxy-acrylamide;

N-hydroxy-3-[4-(3-oxo-3-thiophen-3-yl-propenyl)-phenyl]-acrylamide;

N-hydroxy-3-{4-[3-(3-methoxy-4-morpholin-4-ylmethyl-phenyl)-3-oxo-propenyl]phenyl}-acrylamide;

3-{4-[3-(3,4-difluoro-phenyl)-3-oxo-propenyl]phenyl}-N-hydroxy-acrylamide;

3-{4-[3-(3,5-difluoro-phenyl)-3-oxo-propenyl]phenyl}-N-hydroxy-acrylamide;

3-{4-[3-(2,5-difluoro-phenyl)-3-oxo-propenyl]phenyl}-N-hydroxy-acrylamide;

3-{4-[3-(2,6-difluoro-phenyl)-3-oxo-propenyl]phenyl}-N-hydroxy-acrylamide;

N-hydroxy-3-[3-methoxy-4-(3-oxo-3-thiophen-2-yl-propenyl)-phenyl]-acrylamide;

N-hydroxy-3-[3-methyl-4-(3-oxo-3-thiophen-2-yl-propenyl)-phenyl]-acrylamide;

4-{3-[4-(2-hydroxycarbamoyl-vinyl)-phenyl]-acryloyl}-benzoic acid methyl ester;

3-{3-[4-(2-hydroxycarbamoyl-vinyl)-phenyl]-acryloyl}-benzoic acid methyl ester;

3-{4-[3-(5-chloro-thiophen-2-yl)-3-oxo-propenyl]-phenyl}-N-hydroxy-acrylamide;

N-hydroxy-3-{4-[3-(3-hydroxy-phenyl)-3-oxo-propenyl]-phenyl}-acrylamide;

N-hydroxy-3-(4-{3-[4-(4-methyl-piperazin-1-yl)-phenyl]-3-oxo-propenyl}-phenyl)-acrylamide;

N-hydroxy-3-[2-methoxy-4-(3-oxo-3-phenyl-propenyl)-phenyl]-acrylamide;

3-[2-fluoro-4-(3-oxo-3-phenyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

3-[2-chloro-4-(3-oxo-3-phenyl-propenyl)-phenyl]-N-hydroxy-acrylamide;

N-hydroxy-3-[4-(3-oxo-3-pyridin-3-yl-propenyl)-phenyl]-acrylamide;

N-hydroxy-3-[4-(3-oxo-3-pyridin-2-yl-propenyl)-phenyl]-acrylamide;

N-hydroxy-3-[4-(3-oxo-3-pyridin-4-yl-propenyl)-phenyl]-acrylamide;

N-hydroxy-3-[3-methyl-4-(3-oxo-3-phenyl-propenyl)-phenyl]-acrylamide;

N-hydroxy-3-[3-methoxy-4-(3-oxo-3-phenyl-propenyl)-phenyl]-acrylamide;

3-[3-fluoro-4-(3-oxo-3-pyridin-3-yl-propenyl)-phenyl]-N-hydroxacrylamide;

N-hydroxy-3-[5-(3-oxo-3-phenyl-propenyl)-pyridin-2-yl]-acrylamide;

N-hydroxy-3-{5-[3-(2-methoxy-phenyl)-3-oxo-propenyl]-pyridin-2-yl}-acrylamide;

N-hydroxy-3-[5-(3-oxo-3-thiophen-2-yl-propenyl)-pyridin-2-yl]-acrylamide;

3-{5-[3-(3,4-difluoro-phenyl)-3-oxo-propenyl]-pyridin-2-yl}-N-hydroxy-acrylamide.

3. The method of claim 1 , wherein the cutaneous tumor disease is selected from melanomas and basal carcinomas.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2017
From: DAC S.R.L. IN LIQUIDAZIONE
To: GENEXTRA S.P.A.
Reel/Frame 041539/0105 →
CHANGE OF NAME Recorded Jan 17, 2017
From: DAC S.R.L.
To: DAC S.R.L. IN LIQUIDAZIONE
Reel/Frame 041521/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2011
From: MINUCCI, SAVERIO; PELICCI, PIER GIUSEPPE; MAI, ANTONELLO; BALLARINI, MARCO; GARGIULO, GAETANO; MASSA, SILVIO
To: DAC S.R.L.
Reel/Frame 026955/0032 →
Priority Claims (1)
IT MI2004A1869 · Oct 1, 2004 · national
Continuity (2)
Division 11664187
Related Publication 20100240660A1 · Sep 23, 2010